Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Other hematologic neoplasm 2Sarcoma 1Myeloid 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × STA 9090 × Tumor-Agnostic × Clear all
NCT01183364 2014-09-19

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

Synta Pharmaceuticals Corp.

Phase 1 Completed
27 enrolled
Tumor-Agnostic

Neoplasms

NCT00687934 2014-09-18

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Synta Pharmaceuticals Corp.

Phase 1 Completed
53 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00688116 2014-09-18

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Synta Pharmaceuticals Corp.

Phase 1 Unknown
45 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡